Although there has been a slow decline in tuberculosis (TB) incidence worldwide, the prevalence of drug-resistant TB in most high-burden countries has increased. Drug-resistant TB is associated with high mortality, is a threat to health care workers in TB-endemic countries and is prohibitively
costly, which diverts resources away from drug-susceptible cases. Amplification of resistance means that there is an increasing proportion of patients with multidrug-resistant TB who have extensively drug-resistant TB (XDR-TB) or are programmatically untreatable. Thus, new treatment options
are urgently needed. Bedaquiline (BDQ) is the first new drug specifically developed for TB to be licensed for use in almost 40 years. BDQ has sterilising activity and also shows promise as a component of new treatment-shortening regimens for drug-susceptible TB. Here we review insights from
the field into the use of BDQ, issues relevant to the practising clinician, implications for the selection for antiretroviral therapy, pharmacokinetic issues relevant to clinical practice and implications for combination therapy. Given the increasing prevalence of resistance beyond XDR-TB, we also discuss how the development of resistance to BDQ can be minimised.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Lung Infection and Immunity Unit, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Publication date: December 1, 2016
More about this publication?
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites